SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Epic American Credit and Bond Bubble Laboratory
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Elroy Jetson who wrote (43098)10/9/2005 5:50:18 PM
From: Oblomov  Read Replies (1) of 110194
 
EJ,

This is a very helpful summary. A few questions:

1) you say,


Personally, I prefer the German drug Memantine, which is the metabolized form of Amantadine. I think they now sell it in the U.S. as a drug for Alzheimer's, under the name of Namenda for $60 for 60 tablets.


So your preferred therapy would be Relenza + Namenda, or Relenza + Tamiflu? You're correct about the US branded name of memantine, BTW.

2) You seem quite knowledgeable about these issues. Do you suggest a particular set of texts if I wanted to educate myself similarly?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News